medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2015-16-18-25medsovet-399Research ArticleХроническая обструктивная болезнь легкихChronic obstructive pulmonary diseaseГликопиррония бромид: клиническая эффективность и безопасность при ХОБЛ (обзор клинических исследований)Glycopyrronium bromide: clinical efficacy and safety in patients with COPD (a review of clinical trials)ЧикинаС. Ю.ChikinaS. Y.noemail@neicon.ruАвдеевС. Н.AvdeevS. N.noemail@neicon.ruНаучно-исследовательский институт пульмонологии ФМБА России, МоскваРоссияResearch Institute of Pulmonology, Federal Medical and Biological Agency of Russia, MoscowRussian Federation2015301220150161825Copyright © Чикина С.Ю., Авдеев С.Н., 20152015Чикина С.Ю., Авдеев С.Н.Chikina S.Y., Avdeev S.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/399

Хроническая обструктивная болезнь легких (ХОБЛ) - прогрессирующее заболевание с не полностью обратимой бронхиальной обструкцией, возникающее под воздействием различных факторов (главным из которых является курение) [1, 2]. По данным ряда недавно выполненных исследований, распространенность ХОБЛ в мире у людей старше 40 лет составляет 10,1% (11,8% у мужчин и 8,5% у женщин) [3]. ХОБЛ является одной из наиболее актуальных медико-социальных проблем, это обусловлено не только широкой распространенностью заболевания, но и высоким риском серьезных осложнений, которые приводят к инвалидизации и смертности, в т. ч. трудоспособного населения [1, 2].

Chronic obstructive pulmonary disease (COPD) is a progressive disease with incompletely reversible airflow obstruction that occurs under the impact of various factors (among which smoking is the key factor). [1, 2] According to several recent studies, the incidence of COPD in people over 40 years is 10.1% globally (11.8% for men and 8.5% for women). [3] COPD is one of the most pressing health and social issues not only due to the prevalence of the disease. It also poses a high risk of serious complications resulting in disability and death including for the working population. [1, 2]

хроническая обструктивная болезнь легкихфармакотерапиядлительно действующие антихолинергические препаратыгликопиррония бромидchronic obstructive pulmonary diseasepharmacotherapyReferencesGlobal Initiative for Chronic Obstructive Lung Diseas (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. The 2013 report is available on www.goldcopd.com.Global Initiative for Chronic Obstructive Lung Diseas (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. The 2013 report is available on www.goldcopd.com.Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur. Respir. J., 2004. 23: 932-946.Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur. Respir. J., 2004. 23: 932-946.Buist AS, McBurnie MA, Vollmer WM et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet, 2007. 370: 741-750.Buist AS, McBurnie MA, Vollmer WM et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet, 2007. 370: 741-750.Tashkin DP. Long-acting anticholinergic use in chronic obstructive pulmonary disease: efficacy and safety. Curr. Opin. Pulm. Med, 2010. 16: 97-105.Tashkin DP. Long-acting anticholinergic use in chronic obstructive pulmonary disease: efficacy and safety. Curr. Opin. Pulm. Med, 2010. 16: 97-105.Buhl R, Banerji D. Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD. Int. J. Chron. Obstruct Pulmon. Dis., 2012. 7: 729-741.Buhl R, Banerji D. Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD. Int. J. Chron. Obstruct Pulmon. Dis., 2012. 7: 729-741.Ulrik CS. Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit. Int. J. Chron. Obstruct. Pulmon. Dis., 2012. 7: 673-678.Ulrik CS. Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit. Int. J. Chron. Obstruct. Pulmon. Dis., 2012. 7: 673-678.Sykes DA, Dowling MR, Leighton-Davies J et al. The Influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium. J. Pharmacol. Exp. Ther. 2012. 343: 520-528.Sykes DA, Dowling MR, Leighton-Davies J et al. The Influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium. J. Pharmacol. Exp. Ther. 2012. 343: 520-528.Bartels C, Looby M, Sechaud R, Kaiser G. Determination of the pharmacokinetics of glycopyrronium in the lung using a population pharmacokinetic modeling approach. Br. J. Clin. Pharmacol., 2013. doi: 10.1111/bcp.12118.Bartels C, Looby M, Sechaud R, Kaiser G. Determination of the pharmacokinetics of glycopyrronium in the lung using a population pharmacokinetic modeling approach. Br. J. Clin. Pharmacol., 2013. doi: 10.1111/bcp.12118.Arievich H, Overend T, Renard D et al. Glycopyrronium, an inhaled long-acting muscarinic antagonist: a dose-ranging study in patients with COPD. BMC Pulm. Med., 2012. 12: 74.Arievich H, Overend T, Renard D et al. Glycopyrronium, an inhaled long-acting muscarinic antagonist: a dose-ranging study in patients with COPD. BMC Pulm. Med., 2012. 12: 74.Chapman KR, Fogarty CM, Peckitt C et al. Delivery characteristics and patients' handling of two single-dose dry-powder inhalers used in COPD. Int. J. Chron. Obstruct. Pulmon. Dis., 2011. 6: 353-363.Chapman KR, Fogarty CM, Peckitt C et al. Delivery characteristics and patients' handling of two single-dose dry-powder inhalers used in COPD. Int. J. Chron. Obstruct. Pulmon. Dis., 2011. 6: 353-363.D'Urzo A, Ferguson GT, van Noord JA et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir. Res., 2011. 12: 156.D'Urzo A, Ferguson GT, van Noord JA et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir. Res., 2011. 12: 156.Kerwin E, Hebert J, Gallagher N et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur. Respir. J., 2012. 40: 1106-1114.Kerwin E, Hebert J, Gallagher N et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur. Respir. J., 2012. 40: 1106-1114.Beeh KM, Singh D, Di Scala L, Drollmann A. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int. J. Chron. Obstruct. Pulmon. Dis., 2012. 7: 503-513.Beeh KM, Singh D, Di Scala L, Drollmann A. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int. J. Chron. Obstruct. Pulmon. Dis., 2012. 7: 503-513.Chapman KR, Beeh KM, Beier J et al. A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study. BMCPulm. Med. 2014. 14: 4.Chapman KR, Beeh KM, Beier J et al. A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study. BMCPulm. Med. 2014. 14: 4.Vincken W, Aumann J, Chen H et al. Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study. Int. J. Chron. Obstruct. Pulmon. Dis. 2014. 9: 215-228.Vincken W, Aumann J, Chen H et al. Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study. Int. J. Chron. Obstruct. Pulmon. Dis. 2014. 9: 215-228.Barnes PJ. Theoretical aspects of anticholinergic treatment. In: Gross N (ed.). Anticholinergic therapy in obstructive lung disease. Franklin Scientific Publication, London. 1993: 88-104. Н.Н. МЕЩЕРЯКОВА, к.м.н., Науч но-исследовательский институт пульмонологии ФМБА России, МоскваBarnes PJ. Theoretical aspects of anticholinergic treatment. In: Gross N (ed.). Anticholinergic therapy in obstructive lung disease. Franklin Scientific Publication, London. 1993: 88-104. Н.Н. МЕЩЕРЯКОВА, к.м.н., Науч но-исследовательский институт пульмонологии ФМБА России, Москва

The authors declare that there are no conflicts of interest present.